{"protocolSection": {"identificationModule": {"nctId": "NCT00887588", "orgStudyIdInfo": {"id": "CLCZ696B2214"}, "secondaryIdInfos": [{"id": "2009-010208-27"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction", "officialTitle": "A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-11"}, "primaryCompletionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-22", "studyFirstSubmitQcDate": "2009-04-23", "studyFirstPostDateStruct": {"date": "2009-04-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-07-16", "resultsFirstSubmitQcDate": "2015-07-16", "resultsFirstPostDateStruct": {"date": "2015-08-13", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2013-01-02", "dispFirstSubmitQcDate": "2013-01-02", "dispFirstPostDateStruct": {"date": "2013-01-04", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-12", "lastUpdatePostDateStruct": {"date": "2015-08-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection fraction."}, "conditionsModule": {"conditions": ["Chronic Heart Failure"], "keywords": ["Chronic heart failure", "preserved ejection fraction", "cardiovascular disease", "NT-proBNP", "biomarkers", "Heart failure with preserved left-ventricular ejection", "fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 307, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LCZ696", "type": "EXPERIMENTAL", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.", "interventionNames": ["Drug: LCZ696", "Drug: Placebo"]}, {"label": "Valsartan", "type": "ACTIVE_COMPARATOR", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.", "interventionNames": ["Drug: Valsartan", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "LCZ696", "description": "50 mg, 100 mg and 200 mg tablets", "armGroupLabels": ["LCZ696"]}, {"type": "DRUG", "name": "Valsartan", "description": "40 mg, 80 mg and 160 mg tablets", "armGroupLabels": ["Valsartan"]}, {"type": "DRUG", "name": "Placebo", "description": "matching placebo to LCZ696 and Valsartan", "armGroupLabels": ["LCZ696", "Valsartan"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)", "description": "Evaluation of NT-proBNP was performed by a central laboratory. Change from baseline in NT-proBNP was presented as a ratio where the ratio was calculated as the NT-proBNP value at 12 weeks over the NT-proBNP value at baseline. A ratio \\< 1 indicates improvement.", "timeFrame": "Baseline, 12 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in NT-proBNP and Brain Natriuretic Peptide (BNP)", "description": "Evaluation of NT-proBNP and BNP was performed by a central laboratory. Change from baseline in NT-proBNP and in BNP was presented as a ratio where the ratio for NT-proBNP was calculated as the NT-proBNP value at 36 weeks over the NT-proBNP value at baseline, and the ratio for BNP was calculated as the BNP value at 36 weeks over the BNP value at baseline. A ratio \\< 1 indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Plasma Cyclic Guanine Monophosphate (cGMP)", "description": "Evaluation of cGMP was performed by a central laboratory. Change from baseline in cGMP was presented as a ratio where the ratio was calculated as the cGMP value at 36 weeks over the cGMP value at baseline. A ratio \\< 1 indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography (ECHO) Parameters: Left Ventricular End (LVE) Diastolic Diameter, LVE Systolic Diameter, Septal End Diastolic Thickness, Posterior LV Wall End Diastolic Thickness, Relative Wall Thickness, Left Atrial Dimension", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: LVE Diastolic Volume, LVE Systolic Volume, Left Ventricular Stroke Volume, Left Atrial Volume", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Left Ventricular Ejection Fraction", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Left Ventricular Mass", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Left Ventricular Mass Index", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Left Atrial Volume Index", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Ewave Velocity, A Wave Velocity, e' at Septal Mitral Annulus, e' at Lateral Mitral Annulus", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Ratio of E to A Velocity, E/e' Ratio", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A ratio \\< 1 indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change in Echocardiography Parameters: Isovolumic Relaxation Time", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Echocardiography Parameters: Tricuspid Regurgitation Velocity", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "timeFrame": "Baseline, 36 weeks"}, {"measure": "Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score and Individual Domain Summary Scores", "description": "The KCCQ is a self-administered questionnaire. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and quality of life, each with different Likert scale wording, including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. A positive change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Percentage of Participants With Clinical Composite Assessment of Improved, Unchanged or Worsened", "description": "The clinical composite assessment is defined as follows: Improved = a) participant improved (markedly or moderately) in the global assessment of disease activity with no worsening of NYHA functional class and no major adverse cardiovascular event or b) participant improved in NYHA functional class with no worsening (markedly or moderately) in the global assessment of disease activity and no major adverse cardiovascular event. Worsened = participant worsened (markedly or moderately) in the global assessment of disease activity or in NYHA functional class or experienced a major adverse cardiovascular event. Unchanged = participant does not meet the definition for improved or worsened.", "timeFrame": "36 weeks"}, {"measure": "Percentage of Participants With New York Heart Association (NYHA) Class I, II, II or IV", "description": "The NYHA Functional Classification classifies patients' heart failure according to the severity of their symptoms. The classification is as follows: Class I: no limitation of physical activity, ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath); Class II: slight limitation to physical activity, comfortable at rest, ordinary physical activity results in fatigue, palpitation or dyspnea; Class III: marked limitation of physical activity, comfortable at rest, less than ordinary activity causes fatigue, palpitation or dyspnea; Class IV: unable to carry on any physical activity without discomfort, symptoms of heart failure at rest, if any physical activity is undertaken, discomfort increases.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)", "description": "eGFR was calculated from the serum creatinine concentration determined by central laboratory assessment. A positive change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Serum Creatinine", "description": "Evaluation of serum creatinine was performed by central laboratory. A negative change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Albumin/Creatinine Ratio", "description": "Evaluation of albumin/creatinine was performed by central laboratory. A ratio \\< 1 indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Arterial Stiffness Parameters: Brachial Systolic Blood Pressure (SBP), Brachial Diastolic Blood Pressure (DBP), Central Augmentation Pressure, Central Pressure at T1-DP, Central SBP, Central DBP, Central Mean Pressure", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Arterial Stiffness Parameters: Heart Rate Correct Cen Aug/Pulse Ht", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Arterial Stiffness Parameters: Heart Rate", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Arterial Stiffness Parameters: Pulse Wave Velocity", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}, {"measure": "Change From Baseline in Sitting SBP, Sitting DBP and Sitting Pulse Pressure (PP)", "description": "Sitting blood pressure and sitting pulse pressure were assessed. A negative change from baseline indicates improvement.", "timeFrame": "baseline, 36 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with documented stable chronic heart failure (NYHA II-IV):\n\n  * LVEF \u2265 45% (local measurement, assessed by echocardiography, MUGA, CT scan, MRI or ventricular angiography)\n  * the ejection fraction must have been obtained within 6 months prior to randomization or after any MI or other event that would affect ejection fraction.\n* Plasma NT-proBNP \\> 500 pg/ml at Visit 1.\n* Patients with documented stable chronic heart failure (NYHA II-IV).\n* Patients receiving ACE inhibitors (ACEi), an angiotensin receptor blockers (ARB) and/or a beta blockers must be on a stable dose of these medications stable for the 1 month period prior to Visit 1.\n* Patients must be on diuretic therapy prior to Visit 1 (flexible dosing is permitted).\n* Patients with a controlled systolic BP, defined as a target systolic BP less than 140 mm Hg; participants with BP up to and including 160 mm Hg are eligible for enrollment if they are on three or more medications to control BP at randomization (Visit 2).\n* Patients with at least one of the following symptoms at the time of screening (Visit 1):\n\n  * Dyspnea on exertion\n  * Orthopnea\n  * Paroxysmal nocturnal dyspnea\n  * Peripheral edema\n* Patients must have an eGFR \u2265 30 ml/min/1.73 m2 at Visit 1 (calculated by the Modification of Diet in Renal Disease formula).\n* Patients with a potassium \u22645.2 mmol/l at Visit 1.\n\nExclusion Criteria:\n\n* Patients with a prior LVEF reading \\<45%, at any time.\n* Patients who require treatment with both an ACE inhibitor and an ARB.\n* Isolated right heart failure due to pulmonary disease.\n* Dyspnea and/or edema from non-cardiac causes, such as lung disease, anemia, or severe obesity.\n* Presence of hemodynamically significant mitral and /or aortic valve disease.\n* Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis.\n* Presence of hypertrophic obstructive cardiomyopathy.\n* Other protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "40 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}, {"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Novartis Investigative Site", "city": "Chicago", "state": "Illinois", "zip": "60657", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novartis Investigative Site", "city": "Detroit", "state": "Michigan", "zip": "48201", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Novartis Investigative Site", "city": "Grand Island", "state": "Nebraska", "zip": "68803", "country": "United States", "geoPoint": {"lat": 40.92501, "lon": -98.34201}}, {"facility": "Novartis Investigative Site", "city": "Lincoln", "state": "Nebraska", "zip": "68506", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Tulsa", "state": "Oklahoma", "zip": "74133", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Novartis Investigative Site", "city": "Hillsboro", "state": "Oregon", "zip": "97123", "country": "United States", "geoPoint": {"lat": 45.52289, "lon": -122.98983}}, {"facility": "Novartis Investigative Site", "city": "Wyomissing", "state": "Pennsylvania", "zip": "19610", "country": "United States", "geoPoint": {"lat": 40.32954, "lon": -75.96521}}, {"facility": "Novartis Investigative Site", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Novartis Investigative Site", "city": "Houston", "state": "Texas", "zip": "77025", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1408INH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Ciudad Autonoma de Bs As", "state": "Buenos Aires", "zip": "C1119ACN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Ramos Mejia", "state": "Buenos Aires", "zip": "B1704ETD", "country": "Argentina", "geoPoint": {"lat": -34.6551, "lon": -58.55318}}, {"facility": "Novartis Investigative Site", "city": "San Martin", "state": "Buenos Aires", "zip": "B1650CSQ", "country": "Argentina", "geoPoint": {"lat": -33.08103, "lon": -68.46814}}, {"facility": "Novartis Investigative Site", "city": "Rosario", "state": "Santa Fe", "zip": "S200CVD", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Novartis Investigative Site", "city": "San Miguel de Tucuman", "state": "Tucuman", "zip": "T4000EBR", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Novartis Investigative Site", "city": "Cordoba", "zip": "X5000EPU", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novartis Investigative Site", "city": "Cordoba", "zip": "X5000EVQ", "country": "Argentina", "geoPoint": {"lat": -31.4135, "lon": -64.18105}}, {"facility": "Novartis Investigative Site", "city": "Corrientes", "zip": "W3400", "country": "Argentina", "geoPoint": {"lat": -27.4806, "lon": -58.8341}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "zip": "3000", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Santa Fe", "zip": "S3000FWO", "country": "Argentina", "geoPoint": {"lat": -31.63333, "lon": -60.7}}, {"facility": "Novartis Investigative Site", "city": "Goiania", "state": "GO", "zip": "74605-050", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "Novartis Investigative Site", "city": "Porto Alegre", "state": "RS", "zip": "90610-000", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Novartis Investigative Site", "city": "Sao Jose do Rio Preto", "state": "SP", "zip": "15015-750", "country": "Brazil", "geoPoint": {"lat": -20.81972, "lon": -49.37944}}, {"facility": "Novartis Investigative Site", "city": "S\u00e3o Paulo", "state": "SP", "zip": "05403-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Novartis Investigative Site", "city": "Brampton", "state": "Ontario", "zip": "L6Z 4N5", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"facility": "Novartis Investigative Site", "city": "Montreal", "state": "Quebec", "zip": "H3A 1A1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Novartis Investigative Site", "city": "Montreal", "state": "Quebec", "zip": "H3G 1A4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Novartis Investigative Site", "city": "G\u00f6ttingen", "zip": "D-37075", "country": "Germany", "geoPoint": {"lat": 51.53443, "lon": 9.93228}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Andhra Pradesh, INDIA", "zip": "500034", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "state": "Andhra Pradesh", "zip": "500012", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "New Delhi", "state": "Delhi", "zip": "110060", "country": "India", "geoPoint": {"lat": 28.63576, "lon": 77.22445}}, {"facility": "Novartis Investigative Site", "city": "Mangalore", "state": "Karnataka", "zip": "575002", "country": "India", "geoPoint": {"lat": 12.91723, "lon": 74.85603}}, {"facility": "Novartis Investigative Site", "city": "Manipal", "state": "Karnataka", "zip": "576104", "country": "India"}, {"facility": "Novartis Investigative Site", "city": "Mumbai", "state": "Maharashtra", "zip": "400 022", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "zip": "44000033", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Nagpur", "state": "Maharashtra", "zip": "440012", "country": "India", "geoPoint": {"lat": 21.14631, "lon": 79.08491}}, {"facility": "Novartis Investigative Site", "city": "Jaipur", "state": "Rajasthan", "zip": "302001", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Novartis Investigative Site", "city": "Jaipur", "state": "Rajasthan", "zip": "302004", "country": "India", "geoPoint": {"lat": 26.91962, "lon": 75.78781}}, {"facility": "Novartis Investigative Site", "city": "Hyderabad", "zip": "500 063", "country": "India", "geoPoint": {"lat": 17.38405, "lon": 78.45636}}, {"facility": "Novartis Investigative Site", "city": "Bergamo", "state": "BG", "zip": "24128", "country": "Italy", "geoPoint": {"lat": 45.69601, "lon": 9.66721}}, {"facility": "Novartis Investigative Site", "city": "Cosenza", "state": "CS", "zip": "87100", "country": "Italy", "geoPoint": {"lat": 39.2989, "lon": 16.25307}}, {"facility": "Novartis Investigative Site", "city": "Pisa", "state": "PI", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Novartis Investigative Site", "city": "Casorate Primo", "state": "PV", "zip": "27022", "country": "Italy", "geoPoint": {"lat": 45.31142, "lon": 9.01703}}, {"facility": "Novartis Investigative Site", "city": "Sarzana", "state": "SP", "zip": "19038", "country": "Italy", "geoPoint": {"lat": 44.11178, "lon": 9.9622}}, {"facility": "Novartis Investigative Site", "city": "San Daniele Del Friuli", "state": "UD", "zip": "33038", "country": "Italy", "geoPoint": {"lat": 46.15714, "lon": 13.00726}}, {"facility": "Novartis Investigative Site", "city": "Somma Lombardo", "state": "VA", "zip": "21019", "country": "Italy", "geoPoint": {"lat": 45.68213, "lon": 8.70759}}, {"facility": "Novartis Investigative Site", "city": "Amsterdam", "zip": "1105 AZ", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"facility": "Novartis Investigative Site", "city": "Delft", "zip": "NL 2625 AD", "country": "Netherlands", "geoPoint": {"lat": 52.00667, "lon": 4.35556}}, {"facility": "Novartis Investigative Site", "city": "Ede", "zip": "6716 RP", "country": "Netherlands", "geoPoint": {"lat": 52.03333, "lon": 5.65833}}, {"facility": "Novartis Investigative Site", "city": "Goes", "zip": "4462 RA", "country": "Netherlands", "geoPoint": {"lat": 51.50417, "lon": 3.88889}}, {"facility": "Novartis Investigative Site", "city": "Groningen", "zip": "9713 GZ", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "Heerenveen", "zip": "8441 PW", "country": "Netherlands", "geoPoint": {"lat": 52.95929, "lon": 5.91854}}, {"facility": "Novartis Investigative Site", "city": "Heerlen", "zip": "6419 PC", "country": "Netherlands", "geoPoint": {"lat": 50.88365, "lon": 5.98154}}, {"facility": "Novartis Investigative Site", "city": "Hengelo", "zip": "7555 DL", "country": "Netherlands", "geoPoint": {"lat": 52.26583, "lon": 6.79306}}, {"facility": "Novartis Investigative Site", "city": "Piotrkow Trybunalski", "zip": "97-300", "country": "Poland", "geoPoint": {"lat": 51.40547, "lon": 19.70321}}, {"facility": "Novartis Investigative Site", "city": "Sieradz", "zip": "98-200", "country": "Poland", "geoPoint": {"lat": 51.59584, "lon": 18.73023}}, {"facility": "Novartis Investigative Site", "city": "Warszawa/Anin", "zip": "04-761", "country": "Poland"}, {"facility": "Novartis Investigative Site", "city": "Wroclaw", "zip": "50-981", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Novartis Investigative Site", "city": "Wroclaw", "zip": "51-124", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Novartis Investigative Site", "city": "Craiova", "state": "Jud. Dolj", "zip": "200147", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Novartis Investigative Site", "city": "Craiova", "state": "Jud.Dolj", "zip": "200235", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "Novartis Investigative Site", "city": "Baia Mare", "zip": "430031", "country": "Romania", "geoPoint": {"lat": 47.65529, "lon": 23.57381}}, {"facility": "Novartis Investigative Site", "city": "Pitesti", "zip": "110114", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "117292", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "Moscow", "zip": "121552", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigative Site", "city": "S.-Petersburg", "zip": "196247", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint-Petersburg", "zip": "194044", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Saint-Petersburg", "zip": "197341", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "119074", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "169609", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Sevilla", "state": "Andalucia", "zip": "41009", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novartis Investigative Site", "city": "Hospitalet de Llobregat", "state": "Barcelona", "zip": "08907", "country": "Spain", "geoPoint": {"lat": 41.35967, "lon": 2.10028}}, {"facility": "Novartis Investigative Site", "city": "Alicante", "state": "Comunidad Valenciana", "zip": "03004", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "Novartis Investigative Site", "city": "A Coruna", "state": "Galicia", "zip": "15006", "country": "Spain", "geoPoint": {"lat": 43.37135, "lon": -8.396}}, {"facility": "Novartis Investigative Site", "city": "Santiago de Compostela", "state": "Galicia", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28034", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Madrid", "zip": "28046", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigative Site", "city": "Caracas", "state": "Distrito Capital", "zip": "1010", "country": "Venezuela", "geoPoint": {"lat": 10.48801, "lon": -66.87919}}, {"facility": "Novartis Investigative Site", "city": "Maracaibo", "state": "Estado Zulia", "zip": "4011", "country": "Venezuela", "geoPoint": {"lat": 10.66663, "lon": -71.61245}}]}, "referencesModule": {"references": [{"pmid": "22932717", "type": "BACKGROUND", "citation": "Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012 Oct 20;380(9851):1387-95. doi: 10.1016/S0140-6736(12)61227-6. Epub 2012 Aug 26."}, {"pmid": "30354399", "type": "DERIVED", "citation": "Januzzi JL Jr, Packer M, Claggett B, Liu J, Shah AM, Zile MR, Pieske B, Voors A, Gandhi PU, Prescott MF, Shi V, Lefkowitz MP, McMurray JJV, Solomon SD. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circ Heart Fail. 2018 Oct;11(10):e005133. doi: 10.1161/CIRCHEARTFAILURE.118.005133."}, {"pmid": "26754625", "type": "DERIVED", "citation": "Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD; Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investigators. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016 Jan;9(1):e002551. doi: 10.1161/CIRCHEARTFAILURE.115.002551."}, {"pmid": "26280447", "type": "DERIVED", "citation": "Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):14-22. doi: 10.1111/bcpt.12453. Epub 2015 Sep 4."}, {"pmid": "25277997", "type": "DERIVED", "citation": "Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, Kraigher-Krainer E, Shah AM, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014 Nov;7(6):953-9. doi: 10.1161/CIRCHEARTFAILURE.114.001427. Epub 2014 Oct 2."}, {"pmid": "25138249", "type": "DERIVED", "citation": "Santos AB, Kraigher-Krainer E, Gupta DK, Claggett B, Zile MR, Pieske B, Voors AA, Lefkowitz M, Bransford T, Shi V, Packer M, McMurray JJ, Shah AM, Solomon SD; PARAMOUNT Investigators. Impaired left atrial function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014 Oct;16(10):1096-103. doi: 10.1002/ejhf.147. Epub 2014 Aug 19."}, {"pmid": "24184245", "type": "DERIVED", "citation": "Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, Zile MR, Voors AA, Lefkowitz MP, Packer M, McMurray JJ, Solomon SD; PARAMOUNT Investigators. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014 Feb 11;63(5):447-56. doi: 10.1016/j.jacc.2013.09.052. Epub 2013 Oct 30. Erratum In: J Am Coll Cardiol. 2014 Jul 22;64(3):335."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Eight participants, who completed the core, could not continue in the extension because the 36 week protocol amendment was not yet approved by health authorities; 1 participant, who completed the core, discontinued before the extension start due to an adverse event.", "recruitmentDetails": "A total of 308 participants were randomized to the core 12 week period, but 7 participants were excluded due to major Good Clinical Practice (GCP) violation. Of the 261 participants who completed the core, 252 participants entered the extension period.", "groups": [{"id": "FG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "FG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "periods": [{"title": "Core Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "152"}]}, {"type": "Extension Efficacy Set", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "125"}]}, {"type": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "148"}, {"groupId": "FG001", "numSubjects": "146"}]}, {"type": "Arterial Stiffness Set", "achievements": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "94"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}, {"groupId": "FG001", "numSubjects": "131"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "21"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "11"}]}]}, {"title": "Extension Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "125"}]}, {"type": "Arterial Stiffness Set", "achievements": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "94"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "121"}, {"groupId": "FG001", "numSubjects": "120"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "BG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "149"}, {"groupId": "BG001", "value": "152"}, {"groupId": "BG002", "value": "301"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.9", "spread": "9.38"}, {"groupId": "BG001", "value": "71.2", "spread": "8.94"}, {"groupId": "BG002", "value": "71.0", "spread": "9.15"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "170"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "131"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)", "description": "Evaluation of NT-proBNP was performed by a central laboratory. Change from baseline in NT-proBNP was presented as a ratio where the ratio was calculated as the NT-proBNP value at 12 weeks over the NT-proBNP value at baseline. A ratio \\< 1 indicates improvement.", "populationDescription": "Participants from the full analysis set (FAS), who had both baseline and 12 week values, were included in the analysis. The FAS consisted of all randomized participants who had baseline and at least one post-baseline efficacy measurement during the double blind period.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio: endpoint/baseline (pg/mL)", "timeFrame": "Baseline, 12 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "132"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.83", "lowerLimit": "0.68", "upperLimit": "1.01"}, {"groupId": "OG001", "value": "1.08", "lowerLimit": "0.89", "upperLimit": "1.32"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in NT-proBNP and Brain Natriuretic Peptide (BNP)", "description": "Evaluation of NT-proBNP and BNP was performed by a central laboratory. Change from baseline in NT-proBNP and in BNP was presented as a ratio where the ratio for NT-proBNP was calculated as the NT-proBNP value at 36 weeks over the NT-proBNP value at baseline, and the ratio for BNP was calculated as the BNP value at 36 weeks over the BNP value at baseline. A ratio \\< 1 indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values for each parameter, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio: endpoint/baseline (pg/mL)", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "NT-proBNP (n=115,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.78", "lowerLimit": "0.59", "upperLimit": "1.02"}, {"groupId": "OG001", "value": "0.92", "lowerLimit": "0.70", "upperLimit": "1.21"}]}]}, {"title": "BNP (n=116,113)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.14", "lowerLimit": "0.88", "upperLimit": "1.47"}, {"groupId": "OG001", "value": "0.95", "lowerLimit": "0.73", "upperLimit": "1.23"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Plasma Cyclic Guanine Monophosphate (cGMP)", "description": "Evaluation of cGMP was performed by a central laboratory. Change from baseline in cGMP was presented as a ratio where the ratio was calculated as the cGMP value at 36 weeks over the cGMP value at baseline. A ratio \\< 1 indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio: endpoint/baseline (nmol/L)", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "lowerLimit": "0.78", "upperLimit": "1.03"}, {"groupId": "OG001", "value": "0.85", "lowerLimit": "0.73", "upperLimit": "0.99"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography (ECHO) Parameters: Left Ventricular End (LVE) Diastolic Diameter, LVE Systolic Diameter, Septal End Diastolic Thickness, Posterior LV Wall End Diastolic Thickness, Relative Wall Thickness, Left Atrial Dimension", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values for each parameter, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "LVE diastolic diameter (n=98,107)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.051"}, {"groupId": "OG001", "value": "-0.19", "spread": "0.051"}]}]}, {"title": "LVE systolic diameter (n=98,107)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.12", "spread": "0.044"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.044"}]}]}, {"title": "Septal end diastolic thickness (n=98,106)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.020"}, {"groupId": "OG001", "value": "0.01", "spread": "0.020"}]}]}, {"title": "Post. LV wall end diastolic thickness (n=99,107)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.015"}, {"groupId": "OG001", "value": "0.01", "spread": "0.015"}]}]}, {"title": "Relative wall thickness (n=98,107)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.008"}, {"groupId": "OG001", "value": "0.02", "spread": "0.008"}]}]}, {"title": "Left atrial dimension (n=99,108)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "0.043"}, {"groupId": "OG001", "value": "-0.12", "spread": "0.042"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: LVE Diastolic Volume, LVE Systolic Volume, Left Ventricular Stroke Volume, Left Atrial Volume", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values for each parameter, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ml", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "LVE diastolic volume (n=94,111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.66", "spread": "2.094"}, {"groupId": "OG001", "value": "-14.31", "spread": "2.027"}]}]}, {"title": "LVE systolic volume (n=95,111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.49", "spread": "1.251"}, {"groupId": "OG001", "value": "-9.64", "spread": "1.215"}]}]}, {"title": "LV stroke volume (n=94,111)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.34", "spread": "1.448"}, {"groupId": "OG001", "value": "-4.63", "spread": "1.400"}]}]}, {"title": "Left atrial volume (n=96,112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.08", "spread": "2.133"}, {"groupId": "OG001", "value": "-2.38", "spread": "2.057"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Left Ventricular Ejection Fraction", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent ejection fraction", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "94"}, {"groupId": "OG001", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.62", "spread": "0.778"}, {"groupId": "OG001", "value": "2.90", "spread": "0.755"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Left Ventricular Mass", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "grams (g)", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.26", "spread": "4.145"}, {"groupId": "OG001", "value": "-8.00", "spread": "4.106"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Left Ventricular Mass Index", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "g/m^2", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.95", "spread": "2.249"}, {"groupId": "OG001", "value": "-1.94", "spread": "2.283"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Left Atrial Volume Index", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ml/m^2", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.02", "spread": "1.260"}, {"groupId": "OG001", "value": "-0.88", "spread": "1.237"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Ewave Velocity, A Wave Velocity, e' at Septal Mitral Annulus, e' at Lateral Mitral Annulus", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values for each parameter, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm/s", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "E wave velocity (n=100,112)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "2.947"}, {"groupId": "OG001", "value": "4.12", "spread": "2.897"}]}]}, {"title": "A wave velocity (n=60,68)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "4.199"}, {"groupId": "OG001", "value": "0.59", "spread": "4.265"}]}]}, {"title": "e' at septal mitral annulus (n=79,98)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "spread": "0.266"}, {"groupId": "OG001", "value": "0.98", "spread": "0.260"}]}]}, {"title": "e' at lateral mitral annulus (n=84,96)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.71", "spread": "0.307"}, {"groupId": "OG001", "value": "0.95", "spread": "0.296"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Ratio of E to A Velocity, E/e' Ratio", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A ratio \\< 1 indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values for each parameter, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ratio", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "E to A velocity (n=60,68)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.080"}, {"groupId": "OG001", "value": "0.07", "spread": "0.081"}]}]}, {"title": "E/e' (n=83,95)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.18", "spread": "0.561"}, {"groupId": "OG001", "value": "-0.75", "spread": "0.543"}]}]}]}, {"type": "SECONDARY", "title": "Change in Echocardiography Parameters: Isovolumic Relaxation Time", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "ms", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.002"}, {"groupId": "OG001", "value": "0.01", "spread": "0.002"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Echocardiography Parameters: Tricuspid Regurgitation Velocity", "description": "A limited two-dimensional and Doppler ECHO examination was done to assess ECHO parameters. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "m/s", "timeFrame": "Baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.081"}, {"groupId": "OG001", "value": "0.00", "spread": "0.079"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score and Individual Domain Summary Scores", "description": "The KCCQ is a self-administered questionnaire. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and quality of life, each with different Likert scale wording, including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. A positive change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values for each domain, were included in the analysis for that domain. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Physical limitation (n=117,114)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.27", "spread": "2.528"}, {"groupId": "OG001", "value": "9.88", "spread": "2.516"}]}]}, {"title": "Symptom stability (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.43", "spread": "3.171"}, {"groupId": "OG001", "value": "7.94", "spread": "3.167"}]}]}, {"title": "Symptom frequency (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.38", "spread": "2.582"}, {"groupId": "OG001", "value": "9.16", "spread": "2.577"}]}]}, {"title": "Symptom burden (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.23", "spread": "2.528"}, {"groupId": "OG001", "value": "9.45", "spread": "2.527"}]}]}, {"title": "Total symptom score (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.83", "spread": "2.386"}, {"groupId": "OG001", "value": "9.32", "spread": "2.384"}]}]}, {"title": "Self efficacy (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.24", "spread": "2.427"}, {"groupId": "OG001", "value": "8.77", "spread": "2.419"}]}]}, {"title": "Quality of life (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.13", "spread": "2.706"}, {"groupId": "OG001", "value": "12.50", "spread": "2.702"}]}]}, {"title": "Social limitation (n=113,107)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.99", "spread": "2.878"}, {"groupId": "OG001", "value": "11.04", "spread": "2.936"}]}]}, {"title": "Overall summary score (n=118,116)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.25", "spread": "2.185"}, {"groupId": "OG001", "value": "11.31", "spread": "2.183"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Clinical Composite Assessment of Improved, Unchanged or Worsened", "description": "The clinical composite assessment is defined as follows: Improved = a) participant improved (markedly or moderately) in the global assessment of disease activity with no worsening of NYHA functional class and no major adverse cardiovascular event or b) participant improved in NYHA functional class with no worsening (markedly or moderately) in the global assessment of disease activity and no major adverse cardiovascular event. Worsened = participant worsened (markedly or moderately) in the global assessment of disease activity or in NYHA functional class or experienced a major adverse cardiovascular event. Unchanged = participant does not meet the definition for improved or worsened.", "populationDescription": "Extension efficacy set: the extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.7"}, {"groupId": "OG001", "value": "32.8"}]}]}, {"title": "Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.7"}, {"groupId": "OG001", "value": "53.6"}]}]}, {"title": "Worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.6"}, {"groupId": "OG001", "value": "13.6"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With New York Heart Association (NYHA) Class I, II, II or IV", "description": "The NYHA Functional Classification classifies patients' heart failure according to the severity of their symptoms. The classification is as follows: Class I: no limitation of physical activity, ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath); Class II: slight limitation to physical activity, comfortable at rest, ordinary physical activity results in fatigue, palpitation or dyspnea; Class III: marked limitation of physical activity, comfortable at rest, less than ordinary activity causes fatigue, palpitation or dyspnea; Class IV: unable to carry on any physical activity without discomfort, symptoms of heart failure at rest, if any physical activity is undertaken, discomfort increases.", "populationDescription": "Extension efficacy set: the extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"title": "Baseline, Class I", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8"}, {"groupId": "OG001", "value": "0.8"}]}]}, {"title": "Baseline, Class II", "categories": [{"measurements": [{"groupId": "OG000", "value": "78.7"}, {"groupId": "OG001", "value": "81.6"}]}]}, {"title": "Baseline, Class III", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.5"}, {"groupId": "OG001", "value": "17.6"}]}]}, {"title": "Baseline, Class IV", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Week 36, Class I", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.6"}, {"groupId": "OG001", "value": "7.2"}]}]}, {"title": "Week 36, Class II", "categories": [{"measurements": [{"groupId": "OG000", "value": "74.0"}, {"groupId": "OG001", "value": "78.4"}]}]}, {"title": "Week 36, Class III", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.4"}, {"groupId": "OG001", "value": "14.4"}]}]}, {"title": "Week 36, Class IV", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)", "description": "eGFR was calculated from the serum creatinine concentration determined by central laboratory assessment. A positive change from baseline indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mL/min/1.73m^2", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "126"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.68", "spread": "1.493"}, {"groupId": "OG001", "value": "-7.14", "spread": "1.517"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Serum Creatinine", "description": "Evaluation of serum creatinine was performed by central laboratory. A negative change from baseline indicates improvement.", "populationDescription": "Extension efficacy set: the extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "\u00b5mol/L", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.82", "spread": "2.136"}, {"groupId": "OG001", "value": "10.65", "spread": "2.183"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Albumin/Creatinine Ratio", "description": "Evaluation of albumin/creatinine was performed by central laboratory. A ratio \\< 1 indicates improvement.", "populationDescription": "Participants from the extension efficacy set, who had both baseline and 36 week values, were included in the analysis for that parameter. The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "ratio", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.19", "lowerLimit": "0.85", "upperLimit": "1.66"}, {"groupId": "OG001", "value": "0.74", "lowerLimit": "0.52", "upperLimit": "1.06"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Arterial Stiffness Parameters: Brachial Systolic Blood Pressure (SBP), Brachial Diastolic Blood Pressure (DBP), Central Augmentation Pressure, Central Pressure at T1-DP, Central SBP, Central DBP, Central Mean Pressure", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the arterial stiffness set, who had values for both baseline and week 36, were analyzed. The arterial stiffness set included randomized participants who participated in the arterial stiffness sub-study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"title": "Brachial SBP(n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.27", "spread": "3.935"}, {"groupId": "OG001", "value": "1.47", "spread": "3.670"}]}]}, {"title": "Brachial DBP (n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.68", "spread": "2.279"}, {"groupId": "OG001", "value": "0.79", "spread": "2.165"}]}]}, {"title": "Central augmentation pressure (n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "1.824"}, {"groupId": "OG001", "value": "-0.24", "spread": "1.705"}]}]}, {"title": "Central pressure at T1-DP (n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.92", "spread": "2.071"}, {"groupId": "OG001", "value": "0.02", "spread": "1.941"}]}]}, {"title": "Central SBP (n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.71", "spread": "3.856"}, {"groupId": "OG001", "value": "0.86", "spread": "3.594"}]}]}, {"title": "Central DBP (n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.40", "spread": "2.319"}, {"groupId": "OG001", "value": "0.24", "spread": "2.204"}]}]}, {"title": "Central mean pressure (n=36,44)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.84", "spread": "2.565"}, {"groupId": "OG001", "value": "-0.13", "spread": "2.436"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Arterial Stiffness Parameters: Heart Rate Correct Cen Aug/Pulse Ht", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the arterial stiffness set, who had values for both baseline and week 36, were analyzed. The arterial stiffness set included randomized participants who participated in the arterial stiffness sub-study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percent", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "2.392"}, {"groupId": "OG001", "value": "-2.16", "spread": "2.250"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Arterial Stiffness Parameters: Heart Rate", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the arterial stiffness set, who had values for both baseline and week 36, were analyzed. The arterial stiffness set included randomized participants who participated in the arterial stiffness sub-study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "bpm", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.64", "spread": "2.026"}, {"groupId": "OG001", "value": "-1.32", "spread": "1.905"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Arterial Stiffness Parameters: Pulse Wave Velocity", "description": "A vascular arterial stiffness sub-study was conducted in a subset of participants. Noninvasive arterial tonometry was assessed using the Sphygmor device. Participants had arterial stiffness, pulse wave velocity and central pressures measured. A negative change from baseline indicates improvement.", "populationDescription": "Participants from the arterial stiffness set, who had values for both baseline and week 36, were analyzed. The arterial stiffness set included randomized participants who participated in the arterial stiffness sub-study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm/s", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.44", "spread": "0.731"}, {"groupId": "OG001", "value": "-0.74", "spread": "0.631"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting SBP, Sitting DBP and Sitting Pulse Pressure (PP)", "description": "Sitting blood pressure and sitting pulse pressure were assessed. A negative change from baseline indicates improvement.", "populationDescription": "Extension efficacy set: The extension efficacy set included all randomized participants who had baseline and at least one post-baseline efficacy measurement during the extension period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline, 36 weeks", "groups": [{"id": "OG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid."}, {"id": "OG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"title": "mean SBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.47", "spread": "1.909"}, {"groupId": "OG001", "value": "-2.18", "spread": "1.936"}]}]}, {"title": "mean DBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.28", "spread": "1.188"}, {"groupId": "OG001", "value": "-1.39", "spread": "1.204"}]}]}, {"title": "Pulse pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.24", "spread": "1.482"}, {"groupId": "OG001", "value": "-1.17", "spread": "1.497"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "LCZ696", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.", "seriousNumAffected": 22, "seriousNumAtRisk": 149, "otherNumAffected": 79, "otherNumAtRisk": 149}, {"id": "EG001", "title": "Valsartan", "description": "During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.", "seriousNumAffected": 30, "seriousNumAtRisk": 152, "otherNumAffected": 92, "otherNumAtRisk": 152}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Bradyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 152}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Sick sinus syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Ascites", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Diarrhoea haemorrhagic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Duodenal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Gastric haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Gastritis erosive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Ileus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Device malfunction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Bacterial sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Endocarditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Osteonecrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Adrenal carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Pancreatic carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Carotid artery stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Cerebrovascular insufficiency", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Hyperuricosuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Acute pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 152}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Arterial thrombosis limb", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Femoral arterial stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Peripheral embolism", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 152}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Cardiac failure chronic", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 152}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 152}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 152}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 152}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 152}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 152}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 152}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 152}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 152}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 152}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 152}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 152}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 152}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 152}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 152}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 149}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 152}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "asFound": "Chronic", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "C000549068", "term": "Sacubitril and valsartan sodium hydrate drug combination"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M350410", "name": "Sacubitril and valsartan sodium hydrate drug combination", "asFound": "Pea", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}